KnowBe4 Analysis Finds Security Awareness Training and Simulated Phishing Effective in Reducing Cybersecurity Risk
30.10.2023 13:00:00 CET | Business Wire | Press Release
KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, today announced it has released a new analysis of the effectiveness of security awareness training and simulated phishing on reducing cybersecurity risk, based on data from over 60,000 individual KnowBe4 customer organizations worldwide.
The new KnowBe4 white paper, “Data Confirms Value of Security Awareness Training and Simulated Phishing”, is based on the largest analysis of its kind, with over 32 million individual end users, who took over 493 million Phishing Security Tests (PSTs) and participated in awareness training at least once a year.
Highlights from the study include:
- Groups that did frequent PSTs performed better in detecting simulated phishing campaigns than groups that did not.
- The more frequently that groups did PSTs, the better the users performed on simulated phishing tests. The more PSTs, the better.
- Groups that did weekly PSTs were 2.74 times more effective in reducing risk than groups that only did less than quarterly PSTs.
- The longer a group trained, the better they did on simulated phishing tests.
- Groups that did both training and simulated phishing tests did the best.
“Based on the massive amount of data that we analyzed from around the world, everyone should be conducting frequent simulated phishing tests as part of their security awareness training program to get the highest level of impact and most effective cybersecurity risk reduction,” said Roger Grimes, data-driven defense evangelist, KnowBe4. “Phishing and social engineering account for 70-90% of all malicious data breaches, so focusing on ways to mitigate it are critical to your organization’s overarching cyber defense strategy. We are thrilled to finally have the concrete data to confirm the true value of security awareness training and simulated phishing.”
KnowBe4 customers attest to the important role the platform plays in cyber defense and risk mitigation, along with the overall effectiveness of incorporating security awareness training and simulated phishing into an organization’s cybersecurity strategy:
“Security awareness training and continuous assessment has helped our organization improve our employees' ability to recognize and avoid interacting with suspicious content in their day-to-day roles. Threats are ever evolving and defensive mechanisms will inevitably fail. When they do, it's important to have people engaged and connected to trends and suspicious patterns to act as a last line of defense. KnowBe4 has helped us minimize the effort required from our security team to deliver relevant and beneficial information to our employees,” said D.S., sr. manager, IT Security Operations.
“Our security awareness program is a vital component of our defense-in-depth strategy. There is no combination of technical controls we can ever put in place to mitigate all the risks we face. AiTM and other advanced attacks are only going to increase. Our employees are our most valued assets and the front line of defense for our organization. Partnering with KnowBe4 to build and consistently improve a comprehensive awareness program helps us proactively address new and emerging threats,” said A.B., IT security manager.
To download the new white paper, visit https://www.knowbe4.com/hubfs/Data-Confirms-Value-of-SAT-WP_EN-us.pdf.
About KnowBe4
KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, is used by more than 65,000 organizations around the globe. Founded by IT and data security specialist Stu Sjouwerman, KnowBe4 helps organizations address the human element of security by raising awareness about ransomware, CEO fraud and other social engineering tactics through a new-school approach to awareness training on security. The late Kevin Mitnick, who was an internationally recognized cybersecurity specialist and KnowBe4’s Chief Hacking Officer, helped design the KnowBe4 training based on his well-documented social engineering tactics. Organizations rely on KnowBe4 to mobilize their end users as their last line of defense and trust the KnowBe4 platform to strengthen their security culture and reduce human risk.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231030689199/en/
Contact information
For more information please contact Kathy Wattman at pr@knowbe4.com | 727-474-9950.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
